BioCryst's Q3: CareMed inventory build flatters ORLADEYO as profits roughly double and guidance rises

The quarter in numbers

BioCryst reported total revenues of $180.3 million for the quarter ended September 30, 2026, up 13% year on year, or 24% on a comparable basis excluding European revenue. The company sold its European ORLADEYO business on October 1, 2025, so the comparable figure is the cleaner read on underlying growth. ORLADEYO net revenue was $174.8 million, about 97% of the total.

Profitability improved sharply. GAAP operating profit was $53.3 million against $29.6 million in the third quarter of 2025. Non-GAAP operating profit was $86.5 million against $50.8 million. GAAP net income was $37.9 million (versus $12.9 million), and non-GAAP net income was $71.1 million (versus $34.7 million). The company said it generated positive cash flow in the quarter and ended September with $376.4 million in cash, cash equivalents, restricted cash and investments.

What drove revenue, and a caveat

The company said revenue growth benefited from its transition to CareMed as sole-source specialty pharmacy partner for ORLADEYO shipments to patients. As part of that model, CareMed built an initial inventory of ORLADEYO to support demand and dispensing, which the company described as consistent with customary specialty pharmacy practice. It expects the inventory level to stay relatively stable over time.

The release does not quantify the build. It says only that ORLADEYO revenue excluding European revenue grew year on year when the inventory effect is removed. Readers should treat the headline growth as partly a one-time channel effect. The question for coming quarters is how much of the $174.8 million reflects patient demand and how much reflects stocking. Because the company expects inventory to hold steady, the stocking benefit should not repeat at this scale.

On the product side, the company said the launch of ORLADEYO oral pellets in HAE patients aged 2 to under 12 began in August. It described early reimbursement as strong and said new prescriptions are being filled ahead of its expectations. In October, the FDA approved a supplemental NDA for the once-daily pellet formulation in patients aged 12 and older, so prescribers can offer capsule or pellet across the label.

Costs and margins

Non-GAAP R&D was $37.1 million, against $38.0 million a year earlier. The company said navenibart's pivotal program pushed costs up, but lower BCX17725 spending and the termination of programs tied to the Birmingham closure more than offset it. GAAP R&D excluding stock-based compensation was $52.4 million, including one-time impairment and termination charges. Total R&D restructuring costs comprised $6.3 million in cash and $9.3 million in non-cash charges.

Sales and marketing excluding stock-based compensation was $37.7 million on a GAAP basis (down 15%) and $36.0 million non-GAAP (up 4%). The company said fees tied to the specialty pharmacy transition contributed to the non-GAAP increase. G&A excluding stock-based compensation was $21.0 million GAAP (down 22%) and $19.1 million non-GAAP (down 8%).

Non-GAAP adjustments cover the European business sale, stock-based compensation, Astria acquisition expenses (the deal closed January 23, 2026), Birmingham termination and impairment charges, and workforce reductions. The gap between GAAP and non-GAAP operating profit, $33.2 million, is therefore largely restructuring and deal-related items.

Guidance

The company kept full-year 2026 ORLADEYO revenue guidance at $625 million to $645 million. It raised total revenue guidance to $715 million to $730 million from $690 million to $715 million. It attributed the increase primarily to higher revenue from licensing navenibart rights and higher RAPIVAB orders from international partners, not to ORLADEYO. The unchanged ORLADEYO range, despite a quarter helped by inventory build, suggests the company is not extrapolating that benefit.

Non-GAAP operating expense guidance, excluding stock-based compensation, restructuring and transaction-related costs, improved to $415 million to $425 million from $420 million to $440 million. The company said this was driven mainly by progress on the Birmingham closure. It expects the closure to be substantially complete by year-end, with cash costs of approximately $10 million and annualized savings of approximately $30 million to $35 million once fully realized, excluding savings from other program-related expenses.

Pipeline and portfolio moves

Navenibart, a long-acting plasma kallikrein inhibitor, is in ALPHA-ORBIT, a fully enrolled pivotal HAE study with every-three-month and every-six-month subcutaneous dosing. The company said top-line six- and twelve-month results remain on track for the third quarter of 2027. BCX17725, a KLK5 inhibitor for Netherton syndrome, is in Phase 1. Part 4 is enrolled, and initial patient data are expected by the end of 2026.

The company has discontinued STAR-0310, the atopic dermatitis program acquired with Astria, after concluding its partnering exploration, to focus on rare diseases. It also formed a seven-member Scientific Advisory Board to guide its external R&D strategy.

What to watch next

First, the underlying ORLADEYO demand signal once the CareMed stocking effect passes, and the pace of the pediatric pellet launch and any uptake in the 12-and-older pellet population. Second, the year-end BCX17725 data in Netherton syndrome. Third, the Birmingham closure, to see whether it delivers the savings and the lower opex range. Fourth, navenibart's pivotal readout in the third quarter of 2027, which is the main long-term catalyst the company has laid out.